Human insulin analog-induced lipoatrophy

51Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

OBJECTIVE -To characterize the pathophysiology of recombinant human insulin-induced lipoatrophy. RESEARCH DESION AND METHODS- We performed immunologic laboratory evaluation and skin testing for different insulin analogs and diluents in patients with type 1 diabetes and severe insulin-induced local lipoatrophy. Subcutaneous adipose tissue biopsies of areas of acute (7 days) and chronic insulin administration were examined. Topical sodium cromolyn was applied twice a day to atrophic areas and prophylactically to new sites of insulin administration. RESULTS- Subcutaneous adipose biopsies showed an elevated population of tryptasepositive, chymase-positive degranulated mast cells. Of five patients treated with topical sodium cromolyn, none had new lipoatrophic sites and four showed improvements in old lesions. CONCLUSIONS -Tryptase-positive/chymase-postitive mast cells, known to be sensitive to sodium cromolyn, may contribute to the destructive immune process mediated in response to exogenous insulin. Mast cell stabilizing therapy with topical cromolyn may reverse early and prevent new lipoatrophic lesions. © 2008 by the American Diabetes Association.

Cite

CITATION STYLE

APA

Lopez, X., Castells, M., Ricker, A., Velazquez, E. F., Edward, M. U. N., & Goldfine, A. B. (2008). Human insulin analog-induced lipoatrophy. Diabetes Care, 31(3), 442–444. https://doi.org/10.2337/dc07-1739

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free